Paradigm acquires Amedis to accelerate drug discovery
acquisition of Amedis Pharmaceuticals with the aim of identifying
highly druggable targets and novel compounds for conditions in the
areas of CNS, pain, endocrinology and metabolism.
The transaction will create an enlarged Company with a mix of proprietary biology and chemistry capabilities. The deal also aims to accelerate Paradigm's ability to progress promising therapeutic targets into novel drug candidates, establishing an extremely promising drug discovery company.
Paradigm currently has two programmes in late stage pre-clinical development as well as a pipeline of proprietary targets with clearly defined therapeutic utility.
Nowadays, modern drug discovery is defined as the therapeutic utility of the thousands of uncharacterised human proteins. Unlocking the precise physiological function of these proteins is a vital pre-requisite of rational drug development. Over 1,000 potential druggable targets have already been identified, of which more than a quarter are advanced within biological validation programmes.
Paradigm Therapeutics has a portfolio of novel, therapeutically important patent protected drug targets identified using its in vivo functional genomics technology platform, with several drug discovery programmes ready for lead identification.
The acquisition of Amedis Pharmaceuticals will bring a range of medicinal chemistry expertise to the Company, including a proprietary silicon chemistry platform, as well as medicinal chemistry expertise, together with two pre-clinical programmes in CNS and endocrinology (cancer).
The Company aims to seek collaborative partners to take its pre-clinical leads through clinical development as well as seek out license targets that are not being exploited in house. Post-merger, the Company aims to see a growth rate of around 30 per cent between UK and Singapore operations.
